Monday, May 04, 2026 1:25:45 PM
Good pt Fred . FDA approval will likely be a " Sell the news " event until the first set of warrants are exercised .
So we have to see how the market takes this .
UNCY has to pay Shilpa $10m on delivery of first batch of OLC ( Renazorb ) IIRC and won't have Medicare coverage until TDAPA is completed ...so they will likely be handing out a lot of free samples to test in clinic responses and burning thru cash on hand.
Typically biotech raise $ on FDA approval ...so this first warrant is basically fore filling that function ...its just how people trade around this .
For me it comes down to the deal they make with Fresenius and DaVita . That determines if OLC gets onto the clinic shelves , if the nephrologists at these clinics actively encourage patients to try OLC ...how much supply UNCY is willing to put out there as free samples etc.
As I've mentioned before .
I've been on statins since they were first approved ( Mevacor )
These were low intensity statins until Lipitor came along ( a high intensity statin )
When Lipitor came out I was handed free samples all over the place . First my Cardiologist , then my local MD and later even my wife from a dialysis clinic .
" Hey you're already on a statin ...this is the latest and it works better "..etc
After 3 mths of free Lipitor ...I never went back
I need to do more work on the warrants
Thx for mentioning
Kiwi
PS. Most CEO's are cheerleaders IMHO
So we have to see how the market takes this .
UNCY has to pay Shilpa $10m on delivery of first batch of OLC ( Renazorb ) IIRC and won't have Medicare coverage until TDAPA is completed ...so they will likely be handing out a lot of free samples to test in clinic responses and burning thru cash on hand.
Typically biotech raise $ on FDA approval ...so this first warrant is basically fore filling that function ...its just how people trade around this .
For me it comes down to the deal they make with Fresenius and DaVita . That determines if OLC gets onto the clinic shelves , if the nephrologists at these clinics actively encourage patients to try OLC ...how much supply UNCY is willing to put out there as free samples etc.
As I've mentioned before .
I've been on statins since they were first approved ( Mevacor )
These were low intensity statins until Lipitor came along ( a high intensity statin )
When Lipitor came out I was handed free samples all over the place . First my Cardiologist , then my local MD and later even my wife from a dialysis clinic .
" Hey you're already on a statin ...this is the latest and it works better "..etc
After 3 mths of free Lipitor ...I never went back
I need to do more work on the warrants
Thx for mentioning
Kiwi
PS. Most CEO's are cheerleaders IMHO
Recent UNCY News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/12/2026 11:51:50 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/12/2026 10:30:46 AM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/30/2026 11:04:02 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/30/2026 11:02:10 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/30/2026 11:00:08 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/06/2026 01:11:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/30/2026 11:29:20 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/30/2026 10:32:02 AM
- Unicycive shares gain as FDA accepts resubmitted OLC NDA • IH Market News • 01/29/2026 03:01:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 10:10:14 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/14/2025 10:09:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 02:12:01 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2025 11:39:29 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/28/2025 11:30:13 AM
- UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit • PR Newswire (US) • 10/14/2025 06:55:00 AM
